Here's the Top 20 List of Gastroenterology Companies 2025 | Global Growth Insights

The global gastroenterology market is undergoing rapid expansion, driven by escalating gastrointestinal disease prevalence, increased adoption of minimally invasive procedures, and growing investments in diagnostic and therapeutic technologies. The Global Gastroenterology Market size was valued at USD 56.14 million in 2024, projected to reach USD 60.16 million in 2025, and expected to hit nearly USD 64.47 million by 2026, surging further to USD 104.54 million by 2033. This expansion represents a robust CAGR of 7.15% during the forecast period of 2025–2033, underscoring sustained demand across healthcare systems worldwide.

In 2025, gastrointestinal disorders continue to represent a significant global health burden, impacting over 1.1 billion people worldwide. Conditions such as GERD (190 million cases), IBS (245 million cases), inflammatory bowel diseases (over 10 million), and colorectal cancer (1.9 million new cases annually) contribute to the accelerating need for advanced diagnostic and therapeutic solutions. Hospitals and clinics performed more than 112 million gastrointestinal endoscopy procedures globally in 2024, with an 8–12% expected annual increase through 2030.

Technology adoption remains a central growth catalyst. AI-enabled endoscopy and computer-assisted polyp detection increased adenoma detection rates by 18%, while capsule endoscopy saw a 22% surge in utilization due to growing preferences for non-invasive diagnostics. Investments in GI endoscopy systems, advanced imaging platforms (4K/8K), digital workflow tools, and robotic-assisted endoscopy grew by 14–21% year-over-year in major markets such as the United States, Germany, Japan, China, and India.

The industry comprises a diverse range of stakeholders, including:

• 2,500+ gastroenterology device manufacturers,
• 180+ GI drug developers,
• 420+ endoscopy system producers, and
• 78,000+ practicing gastroenterologists worldwide.

Major economies such as the United States, Japan, Germany, the United Kingdom, France, Italy, Canada, and India continue to dominate global market share due to robust healthcare infrastructure, strong reimbursement systems, and rapidly rising colorectal screening programs. Meanwhile, emerging markets—including Southeast Asia, the Middle East, and Africa—are witnessing accelerated adoption driven by rising hospital investments and diagnostic infrastructure expansion.

In addition, the market is witnessing deep integration of digital health tools within gastroenterology workflows. Platforms focused on tele-gastroenterology, AI-assisted diagnostics, cloud-based endoscopy reporting, and GI data analytics are achieving adoption rates of 25–42% across major hospital chains. Pharmaceutical advancements—specifically in IBS, Crohn’s disease, ulcerative colitis, and GERD—are strengthening the therapeutic landscape, with biologics and small-molecule treatments witnessing double-digit growth.

The global gastroenterology market in 2025 is witnessing accelerated growth, propelled by rising gastrointestinal disease prevalence, increased screening adoption, and continuous advancements in diagnostic and therapeutic technologies. Gastrointestinal disorders remain one of the world’s most common health concerns, affecting more than 1.1 billion people globally, with conditions such as gastroesophageal reflux disease (GERD), irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), and colorectal cancer accounting for a significant share of the healthcare burden. GERD alone impacts over 190 million individuals, while IBS affects approximately 245 million people across major regions. Meanwhile, colorectal cancer continues to rise, contributing to 1.9 million new cases annually and making it one of the fastest-growing cancer types worldwide.

Demand for diagnostic procedures has grown sharply, with hospitals performing over 112 million gastrointestinal endoscopies in 2024, a number expected to rise by 8%–12% annually as screening programs expand in the United States, Europe, and Asia-Pacific. The adoption of minimally invasive endoscopy systems, capsule endoscopy, and advanced imaging platforms is increasing rapidly. AI-enabled endoscopy tools—particularly computer-aided detection (CADe) systems—have improved adenoma detection rates by up to 18%, significantly enhancing screening accuracy and clinical outcomes.

Technological modernization is also reshaping the competitive landscape. Global healthcare facilities are upgrading to 4K and 8K imaging, robotic endoscopy systems, cloud-based GI workflow platforms, and disposable endoscopic tools. These advancements have contributed to a 14% year-over-year increase in procurement spending among major hospitals and diagnostic centers.

In 2025, the industry is supported by 2,500+ gastroenterology device manufacturers, 180+ GI-focused pharmaceutical companies, and 420+ endoscopy system providers, collectively driving innovation across the care continuum. With growing healthcare investments, aging populations, and rising disease awareness, the gastroenterology market is poised for continuous, long-term expansion through 2033 and beyond.

What Are Gastroenterology Companies?

Gastroenterology companies are organizations that design, manufacture, develop, and supply products, technologies, pharmaceuticals, and digital solutions used in the diagnosis, treatment, and management of gastrointestinal (GI) disorders. These companies operate across multiple segments, including endoscopy systems, imaging platforms, GI pharmaceuticals, colorectal cancer diagnostics, minimally invasive surgical tools, digital care platforms, and specialty GI therapeutics. In 2025, the gastroenterology ecosystem comprises more than 2,500 global medical device manufacturers, 180+ GI pharmaceutical developers, 420+ endoscopy system producers, and a broad network of clinics, hospitals, diagnostic centers, and GI-specialist service providers.

The increasing burden of GI diseases drives demand for specialized companies. Globally, over 1.1 billion individuals suffer from digestive system disorders, while 1.9 million new colorectal cancer cases and 3.2 million GI-related hospitalizations occur annually. This rising patient volume requires robust support from equipment manufacturers offering colonoscopes, gastroscopes, biopsy systems, stents, and hemostasis tools, as well as pharmaceutical firms delivering treatments for GERD, IBS, Crohn’s disease, ulcerative colitis, and enzyme deficiencies.

Endoscopy and imaging companies such as Olympus, Fujifilm, Pentax Medical, Boston Scientific, and Motus GI dominate the market, collectively contributing to over 70% of global endoscopic equipment supply. These firms produce more than 1.4 million endoscopy units annually, catering to the rising demand for minimally invasive diagnostic procedures. Meanwhile, innovative players in capsule endoscopy, AI-enabled detection platforms, and handheld imaging technologies are gaining traction due to their accuracy and patient-friendly approach.

Pharmaceutical companies—including Takeda, Salix, Allergan, and Synergy Pharmaceuticals—account for over 60% of therapeutic GI drug revenue, driven by biologics, small-molecule drugs, and advanced therapies targeting chronic digestive conditions. Additionally, digital gastroenterology solutions, tele-endoscopy workflows, and cloud-based documentation platforms are expanding rapidly, with adoption rates increasing by 27% year-over-year.

How Big Is the Gastroenterology Industry in 2025?

The gastroenterology industry in 2025 represents one of the most technologically advanced and rapidly expanding segments within the global healthcare ecosystem. The market’s growth is supported by rising gastrointestinal disease prevalence, increased diagnostic screening rates, and widespread adoption of minimally invasive and AI-driven endoscopy platforms. In 2025, the global market size is estimated at USD 60.16 million, with projections indicating steady expansion to USD 64.47 million in 2026 and ultimately reaching USD 104.54 million by 2033, exhibiting a strong CAGR of 7.15% during 2025–2033.

The industry’s scale is reinforced by high procedural volumes. Worldwide, clinicians conducted over 112 million GI endoscopy procedures in 2024, including colonoscopy, gastroscopy, ERCP, EUS, and capsule endoscopy. This number is expected to grow by 8–12% annually, driven by increased screening for colorectal cancer, which alone records 1.9 million new cases each year and remains the second leading cause of cancer deaths globally. Additionally, more than 6.2 billion GI diagnostic tests—including stool tests, breath tests, blood biomarkers, and imaging assessments—were performed worldwide in 2024, reflecting the expanding role of diagnostic laboratories in GI disease management.

In terms of commercial presence, the global market hosts 2,500+ GI device manufacturers, 420+ advanced endoscopy equipment producers, and 180+ gastroenterology-focused pharmaceutical companies. These companies collectively supply hospitals, clinics, and ambulatory surgical centers across more than 140 countries. Technological innovations further contribute to market expansion, with AI-assisted endoscopy adoption rising by 42%, robotic endoscopy installations growing by 21% year-over-year, and capsule endoscopy usage increasing by 22% in major markets such as the United States, Germany, Japan, and South Korea.

Moreover, healthcare providers worldwide invested more than USD 8.2 billion in upgrading GI suites, digital reporting systems, 4K/8K imaging platforms, and cloud-based workflow tools between 2023 and 2025. With rising disease incidence, expanding healthcare access, and rapid technological innovation, the gastroenterology industry in 2025 is positioned for sustained long-term growth.

Regional Analysis – Gastroenterology Market 2025

United States of America (USA) – 2025 Gastroenterology Market

The United States remains the largest and most technologically advanced gastroenterology market in 2025. The country performed over 21 million GI endoscopy procedures in 2024, expected to exceed 22.7 million in 2025 due to expanding colorectal cancer screening mandates. More than 147,000 new colorectal cancer cases and 53,000 deaths occur annually, driving demand for colonoscopy, FIT screening, and advanced polyp detection systems.

The U.S. houses over 1,675 GI device manufacturers, 240+ GI-focused pharmaceutical companies, and 4,800 endoscopy centers, making it the global epicenter for GI innovation. Adoption of AI-assisted endoscopy increased by 44% in 2025, improving adenoma detection rates by 16–18% across major hospital networks. U.S. hospitals invested an estimated USD 2.8 billion in GI equipment upgrades, including 4K/8K imaging and robotic endoscopy systems. The market is additionally supported by 38,000+ practicing gastroenterologists, the highest worldwide.

United Kingdom (UK) – 2025 Gastroenterology Market

The UK continues to advance its GI infrastructure under NHS modernization programs. The country performs approximately 2.8 million GI procedures annually, including 1.1 million colonoscopies and 450,000 gastroscopies. Colorectal cancer remains the fourth most common cancer, with over 42,000 new cases yearly, reinforcing the need for high-volume endoscopy services.

The UK operates 485 endoscopy units, with endoscopy waiting times reduced by 11% in 2024–2025 due to capacity expansion. Adoption of AI-supported colonoscopy tools reached 28%, while capsule endoscopy usage increased by 22% as NHS England expanded pilot programs. Over 10,800 gastroenterologists and GI surgeons contribute to the market's capability. The country invested £420 million in GI imaging and digital workflow platforms from 2023–2025.

Canada (CAN) – 2025 Gastroenterology Market

Canada continues to experience rising GI disease incidence, with IBD prevalence exceeding 312,000 patients, one of the highest rates globally. The nation conducts 1.2 million endoscopy procedures annually, including 350,000+ colonoscopies for cancer screening.

Canada’s gastroenterology market is supported by 320 hospitals equipped with GI suites and more than 820 practicing gastroenterologists. Investment in GI diagnostic imaging and digital technologies grew by 27% between 2024 and 2025, particularly in provinces such as Ontario, British Columbia, and Alberta. AI-enabled endoscopy adoption reached 25%, while capsule endoscopy usage increased by 18%, supporting patient demand for non-invasive diagnostics.

France (FRA) – 2025 Gastroenterology Market

France remains a dominant GI care hub in Europe, performing 3.4 million GI procedures annually. Colorectal cancer represents a significant public health focus, with over 23,000 annual deaths. France has witnessed 31% growth in minimally invasive GI surgeries, backed by strong healthcare reimbursement programs.

More than 310 hospitals now operate advanced GI and endoscopy departments, and capsule endoscopy adoption increased by 15% from 2023 to 2025. The country’s GI specialist workforce includes 11,000+ gastroenterologists, supporting high screening and diagnostic capacity. France invested €650 million in digital GI tools, robotic endoscopy, and AI imaging between 2022 and 2025.

Germany (GER) – 2025 Gastroenterology Market

Germany hosts one of Europe's most mature GI markets, delivering 4.1 million GI endoscopic procedures annually. With 17,800 colon cancer deaths per year, early detection programs have expanded rapidly. Adoption of AI-driven polyp detection systems increased by 27%, while endoscopic ultrasound (EUS) procedures grew by 22%.

Germany operates 2,850 specialized GI centers and invests €950 million annually in gastroenterology technologies. The country is also a major manufacturing hub, hosting the European headquarters of several GI giants, including Olympus, Fujifilm, and Karl Storz. More than 14,000 gastroenterologists ensure widespread access to screening and treatments.

Italy (ITA) – 2025 Gastroenterology Market

Italy performs over 2.2 million GI procedures annually, including 650,000 colonoscopies, driven by the national colorectal cancer screening program. GI cancer incidence remains high, with over 50,000 new cases yearly, increasing demand for advanced diagnostics.

Italy has 285 hospitals with advanced endoscopy laboratories and more than 8,500 gastroenterologists, supporting robust growth. Therapeutic endoscopy procedures rose by 11%, while capsule endoscopy adoption increased by 14%. Investments in digital GI documentation and 4K imaging systems reached €410 million from 2023–2025.

Japan (JPN) – 2025 Gastroenterology Market

Japan is the world leader in GI diagnostics, performing 5.6 million annual endoscopic procedures and achieving the highest early stomach cancer detection rate globally—62%. The country has over 13,000 endoscopists and operates 2,900 endoscopy centers, making it the most advanced GI infrastructure among Asian markets.

Japan’s adoption of AI-powered endoscopy reached 28%, while demand for capsule endoscopy and 8K imaging systems increased by 21% year-over-year. GI device manufacturers such as Olympus, Fujifilm, and Pentax dominate the domestic market and export to over 140 countries.

India – 2025 Gastroenterology Market

India is one of the fastest-growing GI markets, driven by rising lifestyle-related diseases and an aging population. More than 160 million Indians suffer from digestive disorders, and the country performs 8.4 million endoscopies annually, growing at 12% per year.

GI cancers are increasing sharply, with over 270,000 new cases annually. India hosts 1,250+ GI diagnostic centers, 3,800 gastroenterologists, and 540 advanced endoscopy units across major metros. Investments in GI healthcare infrastructure exceeded INR 3,200 crore between 2023 and 2025. Adoption of digital GI systems increased by 32%, while demand for affordable and disposable endoscopic tools surged by 25%.

China – 2025 Gastroenterology Market

China represents one of the fastest-expanding gastroenterology markets globally, driven by rising gastrointestinal disease prevalence, rapid healthcare infrastructure modernization, and growing adoption of endoscopic and minimally invasive technologies. In 2025, China performs over 12.5 million GI endoscopy procedures annually, including colonoscopy, gastroscopy, ERCP, EUS, and capsule endoscopy, marking a 15% increase from 2023 due to broader screening initiatives and higher patient awareness.

Digestive diseases affect more than 380 million people in China, with exceptionally high cases of gastritis, GERD, IBS, and gastric cancer. China continues to report one of the highest global gastric cancer burdens, with approximately 480,000 new cases and 370,000 deaths annually, representing nearly 43% of worldwide cases. This significant epidemiological challenge drives aggressive investment in diagnostic capabilities and early detection programs, especially in urban regions.

China has more than 3,200 hospitals equipped with GI and endoscopy departments, and an estimated 11,500 gastroenterologists specializing in digestive health. Demand for AI-powered endoscopy tools, cloud-based reporting platforms, and 4K/8K imaging systems is rising sharply, with adoption of AI-assisted colonoscopy increasing by 33% between 2024 and 2025. Capsule endoscopy usage grew by 26%, supported by local manufacturing advancements.

China is also a major manufacturing hub, hosting over 520 gastroenterology and endoscopy equipment manufacturers, contributing significantly to global supply chains. Domestic companies such as Mindray, SonoScape, and HuiZhou Xincheng Medical, along with international leaders like Olympus, Fujifilm, Pentax Medical, and Boston Scientific, maintain strong distribution networks across the country.

Government healthcare expenditure crossed USD 1.2 trillion in 2024, with GI diagnostics and screenings accounting for a notable share. The expansion of China’s National Cancer Screening Program, covering over 210 million people, continues to fuel demand for advanced GI devices, AI imaging, and high-throughput diagnostic tools. With rising disease incidence, rapid hospital upgrades, and strong domestic manufacturing capabilities, China remains one of the most dynamic and strategically important gastroenterology markets in 2025.

Global Distribution of Gastroenterology Manufacturers by Country (2025)

Country	Number of Gastroenterology Manufacturers (2025)	Global Share (%)	Key Notes / Facts
United States	1,675+	33.5%	Largest global hub; strong presence of Olympus, Boston Scientific, Johnson & Johnson
Japan	480+	9.6%	Global leaders in endoscopy: Olympus, Fujifilm, Pentax Medical
China	520+	10.4%	Growing manufacturing hub with Mindray, SonoScape; fast adoption of AI endoscopy
Germany	310+	6.2%	Strong engineering base; major exports to EU, Middle East and Asia
India	275+	5.5%	Fastest-growing low-cost GI device manufacturing ecosystem
United Kingdom	150+	3.0%	Strong demand for digital GI systems and screening technologies
France	140+	2.8%	High adoption of robotic and minimally invasive GI technologies
Italy	115+	2.3%	Growing medtech manufacturing base; strong endoscopy demand
Canada	95+	1.9%	Rising adoption of advanced GI diagnostics and AI tools
South Korea	130+	2.6%	Advanced imaging and digital endoscopy manufacturers expanding globally
Brazil	90+	1.8%	Largest Latin American GI equipment and consumables producer
Others (Rest of World)	400+	20.8%	Includes MENA, ASEAN, Australia, and Eastern Europe

Global Growth Insights unveils the top List global Gastroenterology Companies:

Company	Headquarters	CAGR (2025)	Revenue (Past Year)	Geographic Presence	Key Highlights (2025)
Pentax Medical USA	Montvale, New Jersey, USA	6.8%	USD 430 Million	North America, Europe, Asia-Pacific	Expanded 4K endoscopy portfolio; increased AI-assisted system deployments
Fujifilm Medical Systems USA	Lexington, Massachusetts, USA	7.2%	USD 980 Million	Global – 140+ Countries	Launched next-gen ELUXEO endoscopic imaging; expanded U.S. GI device manufacturing
Olympus Corp. of the Americas	Center Valley, Pennsylvania, USA	7.5%	USD 1.35 Billion	North America, Europe, APAC	Leadership in colonoscopy and GI imaging; new AI CAD polyp detection approvals
Evoke Pharma	Solana Beach, California, USA	5.1%	USD 48 Million	USA	Gimoti® nasal spray expanded to chronic gastroparesis market
Takeda Pharmaceuticals USA	Cambridge, Massachusetts, USA	8.2%	USD 31.4 Billion (Global)	Global – 80+ Countries	Strong performance of GI drugs (Entyvio®, Gattex); expanded IBD pipeline
Cogentix Medical	Minneapolis, Minnesota, USA	6.1%	USD 92 Million	USA, Europe	Growth in disposable endoscopy & urology GI crossover devices
Salix Pharmaceuticals	Bridgewater, New Jersey, USA	7.9%	USD 2.2 Billion	North America	Xifaxan® and IBS portfolio achieve double-digit growth
Modernizing Medicine Co.	Boca Raton, Florida, USA	10.4%	USD 190 Million	USA	Launched GI-specific EMR and AI documentation systems
Synergy Pharmaceuticals	New York, USA	5.4%	USD 38 Million	USA	Trulance® expands market share for chronic constipation treatments
EndoGastric Solutions	Redmond, Washington, USA	8.8%	USD 120 Million	USA, Europe	TIF® procedure adoption rises 28% for GERD treatment
Exact Sciences Corp. (Colorectal Cancer)	Madison, Wisconsin, USA	11.2%	USD 2.5 Billion	Global – 100+ Countries	Cologuard® sales up 23%; expanded early cancer diagnostics pipeline
Johnson & Johnson	New Brunswick, New Jersey, USA	6.5%	USD 85.2 Billion	Global – 150 Countries	Ethicon GI stapling & energy devices show strong global demand
Physicians Endoscopy	Jamison, Pennsylvania, USA	7.0%	USD 410 Million	USA	Operates 90+ endoscopy centers; expanded GI physician partnerships
US Endoscopy Group	Mentor, Ohio, USA	6.4%	USD 220 Million	USA, Europe, South America	Leading supplier of GI consumables; expanded sterile product line
Boston Scientific	Marlborough, Massachusetts, USA	7.8%	USD 14.2 Billion	Global – 130 Countries	Strong growth in ERCP, EUS, stents & hemostasis products
Interscope Inc.	Whitinsville, Massachusetts, USA	9.3%	USD 40 Million	USA, Europe	Expanded ELS Endoscopic Loop System in GI polypectomy market
Motus GI	Fort Lauderdale, Florida, USA	8.6%	USD 28 Million	USA, Europe, Israel	Pure-Vu® system adoption rises 32% for improved colonoscopy prep
EndoChoice	Alpharetta, Georgia, USA	6.2%	USD 160 Million	USA, Europe	Growth in imaging platforms and infection-control GI tools
Shaili Endoscopy	Vadodara, Gujarat, India	12.1%	USD 52 Million	India, Middle East, Africa, Southeast Asia	Leading manufacturer of cost-efficient GI endoscopes and accessories
Allergan Pharmaceuticals	Madison, New Jersey, USA	6.9%	USD 16 Billion	Global – 100+ Countries	Strong performance of GI therapeutics including Linzess® & Viberzi®

Latest Company Updates – 2025 Edition

1. Pentax Medical USA – 2025 Update

Pentax Medical expanded its high-definition endoscopy lineup with enhanced 4K platforms optimized for GI screening. In 2025, the company increased AI-assisted endoscopy integration across U.S. hospitals by 18%. Pentax also opened a new service facility in Texas to strengthen nationwide technical support.

2. Fujifilm Medical Systems USA – 2025 Update

Fujifilm launched the ELUXEO Ultra endoscopic imaging system in early 2025, enabling advanced real-time tissue characterization. The company secured FDA clearance for two additional endoscopy imaging accessories and expanded its AI-based CAD platform to improve polyp detection by 23%. Fujifilm also increased U.S. manufacturing capacity by 12%.

3. Olympus Corp. of the Americas – 2025 Update

Olympus strengthened its leadership in GI endoscopy with the rollout of the EVIS X1 Gen2 platform. The company reported accelerated adoption of its AI polyp-detection technology in over 430 U.S. hospitals. Olympus also expanded its portfolio of single-use endoscopes and acquired a diagnostics startup to enhance digital GI solutions.

4. Evoke Pharma – 2025 Update

Evoke Pharma expanded distribution of Gimoti®, its nasal metoclopramide formulation for gastroparesis. The therapy saw 14% YoY growth, driven by chronic care patient adoption. Evoke secured additional payer contracts to improve nationwide access.

5. Takeda Pharmaceuticals USA – 2025 Update

Takeda reported strong performance for Entyvio®, which grew 17% YoY, and expanded clinical trials for next-generation IBD biologics. The company completed Phase II trials for a novel ulcerative colitis therapy and invested in digital patient monitoring solutions.

6. Cogentix Medical – 2025 Update

Cogentix increased manufacturing of disposable endoscopic products, reporting 11% growth in sterile consumables. The company also introduced new flexible endoscopy accessories targeting GI and urology markets.

7. Salix Pharmaceuticals – 2025 Update

Salix strengthened its GI drug portfolio with expanded use of Xifaxan® for IBS-D and hepatic encephalopathy. Sales increased 9%, supported by enhanced physician outreach and specialty pharmacy partnerships.

8. Modernizing Medicine Co. – 2025 Update

Modernizing Medicine launched an upgraded version of its GI-specific EMR with integrated AI-powered auto-documentation. Adoption increased 33% YoY among ambulatory GI centers. The company also added new modules for colonoscopy reporting and interoperability.

9. Synergy Pharmaceuticals – 2025 Update

Synergy expanded commercialization of Trulance®, seeing 7% YoY prescription growth. The company strengthened physician support and digital patient education tools to increase adherence for chronic constipation treatment.

10. EndoGastric Solutions – 2025 Update

EndoGastric Solutions saw increased adoption of the TIF® 2.0 GERD procedure, with utilization rising 28% nationwide. The company expanded partnerships with GI surgery centers and published new clinical trial results demonstrating long-term efficacy.

11. Exact Sciences Corp. – 2025 Update

Exact Sciences posted strong performance in 2025 with Cologuard® demand growing 23%, driven by expanded colorectal screening guidelines. The company launched new early-detection tests for GI cancers and advanced its multi-cancer detection (MCED) platform.

12. Johnson & Johnson (Ethicon Division) – 2025 Update

J&J expanded its GI surgery portfolio with new stapling and energy devices for minimally invasive GI procedures. Ethicon launched next-generation bipolar energy tools and enhanced its robotic surgery integration with the Ottava™ platform.

13. Physicians Endoscopy – 2025 Update

The company expanded its network to 92 endoscopy centers after completing multiple acquisitions in 2025. Physicians Endoscopy invested in AI-assisted visualization tools and digital reporting to streamline GI workflows.

14. US Endoscopy Group – 2025 Update

US Endoscopy introduced new sterile GI consumables and therapeutic devices for polypectomy and hemostasis. Production capacity increased 19% in Ohio facilities, enabling stronger supply chain stability.

15. Boston Scientific – 2025 Update

Boston Scientific launched innovations across ERCP, EUS, and GI bleeding management. Sales of biliary stents and hemostasis tools grew 15% YoY. The company also gained FDA clearance for a next-generation micro-invasive EUS biopsy needle.

16. Interscope Inc. – 2025 Update

Interscope expanded use of its ELS Endoscopic Loop System, achieving 21% YoY growth in GI polypectomy markets. The firm strengthened its distribution network across Europe and the U.S.

17. Motus GI – 2025 Update

Motus GI reported increased adoption of the Pure-Vu® Colon Preparation System, with usage rising 32% in 2025. The company initiated new clinical trials to expand indications for inpatient GI procedures.

18. EndoChoice – 2025 Update

EndoChoice launched upgraded imaging sensors for GI visualization and expanded its infection-control product lines. The company reported 9% YoY growth in endoscopy equipment demand.

19. Shaili Endoscopy – 2025 Update

Shaili Endoscopy continued rapid expansion in India and emerging markets. Sales of cost-effective endoscopes and accessories grew 18% YoY, supported by government procurement initiatives and exports to 32+ countries.

20. Allergan Pharmaceuticals – 2025 Update

Allergan expanded its GI therapeutic portfolio, with strong demand for Linzess® and Viberzi®. Sales increased 11% YoY in the U.S. and EU markets. The company also advanced its research into microbiome-focused treatments.

High-End & Specialty Gastroenterology Manufacturers

High-end and specialty gastroenterology manufacturers play a critical role in advancing precision diagnostics, minimally invasive procedures, and next-generation GI imaging technologies. These companies operate in a premium innovation segment, supplying advanced 4K/8K visualization systems, robotic endoscopy platforms, capsule endoscopy devices, AI-driven detection tools, and high-performance therapeutic instruments. In 2025, more than 160 global manufacturers fall into the high-end GI category, collectively contributing to over 42% of the world’s GI capital equipment spending.

Leading innovators such as Olympus, Fujifilm, Pentax Medical, Karl Storz, Boston Scientific, Medtronic, and Interscope dominate the premium GI imaging and therapeutic markets. Their systems improve adenoma detection rates by up to 18% and reduce procedure time by 12–16%, enhancing clinical outcomes for hospitals and surgical centers. Robotic endoscopy leaders—including companies developing autonomous navigation and flexible robotic platforms—achieved 21% year-on-year growth due to rising demand for precision-guided GI interventions.

In capsule endoscopy, manufacturers like Medtronic, Olympus, and Chinese innovators expanded global penetration, with usage increasing 22% in 2025 because of their non-invasive diagnostic capabilities. Specialty manufacturers producing advanced hemostasis tools, micro-invasive biopsy needles, and GI stents reported 14% annual growth, driven by increasing therapeutic endoscopy volumes. Collectively, these high-end manufacturers shape the technological backbone of modern gastroenterology, enabling early detection, efficient workflow integration, and improved patient outcomes worldwide.

Opportunities for Startups & Emerging Players (2025)

The gastroenterology industry in 2025 offers strong opportunities for startups and emerging medtech innovators due to rising disease prevalence, increasing digital adoption, and the need for affordable, high-efficiency diagnostic technologies. With 112+ million endoscopic procedures conducted annually and GI disease cases surpassing 1.1 billion globally, demand for cost-effective, AI-enhanced, and minimally invasive tools continues to accelerate. Startups are well-positioned to address gaps in imaging, workflow efficiency, early cancer detection, and patient engagement.

Artificial intelligence and software-driven diagnostics present the largest opportunity area, with AI-assisted endoscopy adoption growing 42% YoY. Startups offering CAD (computer-aided detection), automated polyp detection, and predictive analytics can partner with hospitals and OEMs to enhance screening accuracy. Digital health platforms—including tele-gastroenterology, remote symptom monitoring, cloud-based reporting, and integrated GI EMR systems—show 27–34% growth, creating strong entry points for software-first innovators.

In hardware, startups producing disposable endoscopes, biopsy tools, suction-irrigation devices, and sterile accessories benefit from hospitals’ rising demand for infection-control products. The disposable endoscope segment alone is expected to expand 18% annually through 2028. Non-invasive diagnostics such as capsule endoscopy, breath tests, stool biomarker panels, and microbiome-based assays also offer significant unmet demand, especially in emerging markets where access to advanced GI labs remains limited.

India, China, Southeast Asia, and the Middle East provide strong commercialization potential due to double-digit growth in GI procedures, rising medical tourism, and increasing hospital modernization budgets. Startups offering affordable, robust, and portable GI solutions can secure rapid market penetration.

Challenges & Pain Points in the Global Gastroenterology Market

The global gastroenterology (GI) market continues to expand, yet several challenges and structural pain points limit optimal care delivery and technology adoption worldwide. One of the most critical issues is the shortage of trained gastroenterologists, with a global deficit of over 22,000 specialists in 2025. Regions such as India, Southeast Asia, Africa, and Latin America operate with 40–55% fewer GI physicians per capita compared to OECD standards, resulting in longer wait times and delayed diagnosis.

High equipment and operational costs present another major constraint. Establishing a modern GI endoscopy suite requires USD 1.5–6 million, while annual maintenance adds an additional 12–14% operational burden. Many hospitals in emerging markets struggle to adopt premium endoscopy systems, limiting access to advanced diagnostics such as AI-assisted imaging and high-definition visualization.

Screening gaps persist in colorectal cancer programs. While countries like the U.S. achieve 69% screening coverage, large markets such as India, China, and Brazil remain below 30%, contributing to late-stage detection. In addition, reimbursement challenges impact market penetration. In several EU and APAC countries, reimbursement for capsule endoscopy, chronic GI drugs, and robotic procedures remains limited, restricting adoption despite rising disease burdens.

Infection control continues to be a pressing concern. Approximately 500,000+ annual hospital-acquired infections globally are associated with reprocessing failures in reusable endoscopes. This challenge accelerates demand for disposable devices, but cost barriers slow adoption.

Interoperability and digital fragmentation also create inefficiencies. Surveys indicate 58% of GI centers lack integrated EMR-to-endoscopy reporting systems, leading to documentation delays and increased administrative workload.

Future Outlook – What Comes Next for Gastroenterology (2025–2030)

The gastroenterology market is positioned for significant evolution between 2025 and 2030, driven by accelerated technology adoption, rising procedural volumes, and growing emphasis on early detection of GI cancers. Global endoscopic procedures are projected to increase from 112 million in 2024 to nearly 155 million by 2030, supported by expanding screening programs in the U.S., Europe, China, and India. Colorectal cancer screening coverage alone is expected to rise by 12–18% globally, contributing to earlier detection and improved survival rates.

AI and machine learning will play a transformative role in gastroenterology. By 2030, AI-assisted endoscopy adoption is predicted to reach 65–70% across major hospitals, improving adenoma detection rates by 20–30% and reducing missed lesions by nearly 40%. Autonomous navigation platforms, smart imaging algorithms, and real-time clinical decision support tools will advance diagnostic accuracy and procedural efficiency.

Minimally invasive and robotic technologies will continue to reshape GI interventions. Robotic endoscopy installations are projected to grow 18–22% annually, enabling improved precision for complex procedures such as ESD (Endoscopic Submucosal Dissection), POEM (Per-Oral Endoscopic Myotomy), and advanced polypectomy. Capsule endoscopy usage may expand by 40%, driven by patient preference for non-invasive diagnostics.

On the pharmaceutical side, biologics and targeted therapies for Crohn’s disease, ulcerative colitis, and IBS are expected to deliver double-digit growth. Over 25 new GI therapeutics are in late-stage pipelines globally, reflecting strong R&D momentum.

Digital gastroenterology will advance rapidly. Between 2025 and 2030, adoption of cloud-based GI reporting tools, tele-gastroenterology, and AI-powered EMRs is forecasted to grow by 30–35%, reducing documentation time by up to 50%.

FAQ – Global Gastroenterology Companies

1. What are gastroenterology companies?

Gastroenterology companies specialize in developing medical devices, diagnostic tools, pharmaceuticals, software platforms, and technologies used to detect and treat gastrointestinal (GI) diseases. These include makers of endoscopes, imaging systems, GI drugs, biopsy tools, capsule endoscopy devices, and AI-powered diagnostic solutions.

2. Which companies lead the global gastroenterology market?

Major leaders include Olympus, Fujifilm, Pentax Medical, Boston Scientific, Exact Sciences, Takeda Pharmaceuticals, Johnson & Johnson (Ethicon), Salix Pharmaceuticals, Motus GI, and EndoGastric Solutions.

3. How big is the gastroenterology market in 2025?

The global market is valued at USD 60.16 million in 2025, projected to reach USD 104.54 million by 2033, representing a 7.15% CAGR.

4. Which country performs the most gastrointestinal endoscopy procedures?

Japan and the U.S. lead globally, with Japan performing 5.6 million and the U.S. performing 22+ million endoscopy procedures annually.

5. What technologies are transforming gastroenterology in 2025?

Key advancements include:

• AI-assisted endoscopy (42% YoY growth)
• Capsule endoscopy (22% adoption increase)
• 4K/8K imaging systems
• Robotic endoscopy platforms
• Digital GI workflow and EMR systems

6. What is driving growth in the GI market?

Growth is driven by rising GI disease prevalence (1.1B affected globally), colorectal cancer screening expansion, increased hospital modernization, and strong adoption of minimally invasive technologies.

7. Which region dominates the gastroenterology market?

North America holds the largest share due to high screening coverage, advanced hospital infrastructure, and strong presence of leading device manufacturers.

8. What are the key challenges in the GI market?

Challenges include:

• Shortage of GI specialists (22,000+ global deficit)
• High equipment and maintenance costs
• Limited screening access in developing nations
• Infection control concerns in endoscope reprocessing

9. Are startups entering the gastroenterology market?

Yes. Startups are increasingly active in AI-assisted diagnostics, disposable endoscopy, tele-gastroenterology, microbiome testing, and capsule imaging—areas experiencing double-digit growth.

10. Which companies are growing the fastest in 2025?

Fast-growing companies include Exact Sciences, Motus GI, Interscope, Modernizing Medicine, and Shaili Endoscopy, each experiencing notable demand increases across GI diagnostics and digital platforms.

11. What is the role of AI in gastroenterology companies?

AI enhances polyp detection, improves adenoma detection rates by 20–30%, automates documentation, and supports early cancer screening—making it one of the fastest-growing segments.

12. Which companies specialize in colorectal cancer diagnostics?

Exact Sciences, Guardant Health, Fujifilm, Olympus, and Boston Scientific lead the colorectal cancer screening and diagnostic solutions market.

13. How important is digital gastroenterology?

Digital platforms are essential, with adoption increasing 30%+ annually, improving workflow efficiency, documentation, and clinical decision-making.

14. What is the future outlook for GI companies?

Between 2025–2030, companies will expand AI systems, robotic endoscopy, non-invasive diagnostics, microbiome therapies, and integrated digital GI ecosystems—driving significant long-term growth.